國立虎尾科技大學 |

Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1./
Author:	Estevez-Ordonez, Dagoberto.
Description:	1 online resource (272 pages)
Notes:	Source: Dissertations Abstracts International, Volume: 85-06, Section: B.
Contained By:	Dissertations Abstracts International85-06B.
Subject:	Medicine. -
Online resource:	click for full text (PQDT)
ISBN:	9798381187601

Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1.
Estevez-Ordonez, Dagoberto.

Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1. - 1 online resource (272 pages)

Source: Dissertations Abstracts International, Volume: 85-06, Section: B.

Thesis (Ph.D.)--The University of Alabama at Birmingham, 2024.

Includes bibliographical references

This dissertation covers data from published and pre-published studies exploring challenges and opportunities in the treatment of malignant glioma with emphasis in glioblastoma and oncolytic immunovirotherapy with an oncolytic herpes simplex virus type 1 (HSV-1) designed to induce expression of IL-12, M002 (murine IL-12) and M032 (human IL-12).It starts with the report of a study that uncovered important racial and socioeconomic disparities experienced by patients with glioblastoma treated in Alabama. Notable results also include the unexpected finding of increased survival in African American patients with glioblastoma even after controlling for factors associated with survival and socioeconomic disparities. The implications of this finding are discussed. This is followed by three in-depth reviews are also included, providing essential background in oncolytic immunovirotherapy as well as unique advantages of using HSV- 1 as oncolytic virus model for brain tumors, in particular high-grade glioma with particular emphasis in glioblastoma.Effective treatment options are limited for patients diagnosed with malignant glioma, and outcomes remain very poor. Recurrence and progression rates are universal with a subsequent historical median overall survival (mOS) of 6.5 months. Preclinical data showed that a second-generation oncolytic herpes virus (oHSV) armed to induce IL- 12 expression was a more effective anti-glioma agent than the first-generation oHSV.Results from an ongoing phase I clinical trial in pet dogs with high-grade glioma are discussed. It also includes results from an open-label, dose-escalating phase I trial designed to determine the safety and tolerability of intratumoral injection of the M032 virus in patients with recurrent or progressive MG. Patients in this study underwent stereotactic placement of up to four intratumoral catheters in enhancing tumor. The following day, M032 (starting at a dose of 105 plaque-forming units, PFU) was infused over a period of 6 hours. The primary endpoint was to determine the safety and maximum tolerated dose. Dose elevations were made using a modified Continual Reassessment Method with 7 dosing cohorts. Secondary endpoints were (1) to determine a recommended dose level for subsequent trials and (2) to obtain biologic data to optimize future studies.Twenty-one patients with recurrent MG ages 19 to 71 received M032 (16 Males, 5 Females). Fourteen patients had IDH wild-type tumors, and eighteen had unmethylated MGMT status. Four grade 1, two grade 2, two grade 3, and two grade 4 adverse events were identified as possibly associated with M032. Both grade 3 and grade 4 adverse events possibly associated with M032 occurred in a single patient on the 108 PFU cohort. No serious adverse events at the maximally plan dose were attributed to M032. Median post treatment survival was 9.38 months (95% confidence interval, 7.57 to 12.95). As of April 5th, 2023; 2 participants were still alive following treatment.Intratumoral M032 had an acceptable adverse-event profile. We observed two grade 3 and two grade 4 adverse events, occurring in a single patient with a large tumor prompting an amendment to tumor size inclusion criteria. No dose-limiting toxicity occurred at maximum planned dose. Preliminary evidence suggests favorable response in some patients with recurrent or progressive MG. Careful selection of patients is needed when considering treatment with M032.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2024

Mode of access: World Wide Web

ISBN: 9798381187601Subjects--Topical Terms:

644133
Medicine.
Subjects--Index Terms:

GlioblastomaIndex Terms--Genre/Form:

554714
Electronic books.

Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1.
LDR:04871ntm a22003857 4500 001 1148729
005 20240930100130.5
006 m o d
007 cr bn ---uuuuu
008 250605s2024 xx obm 000 0 eng d
020 $a 9798381187601
035 $a (MiAaPQ)AAI30689974
035 $a AAI30689974
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Estevez-Ordonez, Dagoberto. $3 1474771
245 1 0 $a Challenges and Opportunities in Glioblastoma and Immunovirotherapy With Oncolytic Herpes Simplex Virus Type 1.
264 0 $c 2024
300 $a 1 online resource (272 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertations Abstracts International, Volume: 85-06, Section: B.
500 $a Advisor: Miller, C. Ryan;Markert, James M.
502 $a Thesis (Ph.D.)--The University of Alabama at Birmingham, 2024.
504 $a Includes bibliographical references
520 $a This dissertation covers data from published and pre-published studies exploring challenges and opportunities in the treatment of malignant glioma with emphasis in glioblastoma and oncolytic immunovirotherapy with an oncolytic herpes simplex virus type 1 (HSV-1) designed to induce expression of IL-12, M002 (murine IL-12) and M032 (human IL-12).It starts with the report of a study that uncovered important racial and socioeconomic disparities experienced by patients with glioblastoma treated in Alabama. Notable results also include the unexpected finding of increased survival in African American patients with glioblastoma even after controlling for factors associated with survival and socioeconomic disparities. The implications of this finding are discussed. This is followed by three in-depth reviews are also included, providing essential background in oncolytic immunovirotherapy as well as unique advantages of using HSV- 1 as oncolytic virus model for brain tumors, in particular high-grade glioma with particular emphasis in glioblastoma.Effective treatment options are limited for patients diagnosed with malignant glioma, and outcomes remain very poor. Recurrence and progression rates are universal with a subsequent historical median overall survival (mOS) of 6.5 months. Preclinical data showed that a second-generation oncolytic herpes virus (oHSV) armed to induce IL- 12 expression was a more effective anti-glioma agent than the first-generation oHSV.Results from an ongoing phase I clinical trial in pet dogs with high-grade glioma are discussed. It also includes results from an open-label, dose-escalating phase I trial designed to determine the safety and tolerability of intratumoral injection of the M032 virus in patients with recurrent or progressive MG. Patients in this study underwent stereotactic placement of up to four intratumoral catheters in enhancing tumor. The following day, M032 (starting at a dose of 105 plaque-forming units, PFU) was infused over a period of 6 hours. The primary endpoint was to determine the safety and maximum tolerated dose. Dose elevations were made using a modified Continual Reassessment Method with 7 dosing cohorts. Secondary endpoints were (1) to determine a recommended dose level for subsequent trials and (2) to obtain biologic data to optimize future studies.Twenty-one patients with recurrent MG ages 19 to 71 received M032 (16 Males, 5 Females). Fourteen patients had IDH wild-type tumors, and eighteen had unmethylated MGMT status. Four grade 1, two grade 2, two grade 3, and two grade 4 adverse events were identified as possibly associated with M032. Both grade 3 and grade 4 adverse events possibly associated with M032 occurred in a single patient on the 108 PFU cohort. No serious adverse events at the maximally plan dose were attributed to M032. Median post treatment survival was 9.38 months (95% confidence interval, 7.57 to 12.95). As of April 5th, 2023; 2 participants were still alive following treatment.Intratumoral M032 had an acceptable adverse-event profile. We observed two grade 3 and two grade 4 adverse events, occurring in a single patient with a large tumor prompting an amendment to tumor size inclusion criteria. No dose-limiting toxicity occurred at maximum planned dose. Preliminary evidence suggests favorable response in some patients with recurrent or progressive MG. Careful selection of patients is needed when considering treatment with M032.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2024
538 $a Mode of access: World Wide Web
650 4 $a Medicine. $3 644133
650 4 $a Virology. $3 644995
650 4 $a Oncology. $3 593951
653 $a Glioblastoma
653 $a Herpes simplex virus type 1
653 $a Immunovirotherapy
653 $a Oncolytic virus
655 7 $a Electronic books. $2 local $3 554714
690 $a 0564
690 $a 0720
690 $a 0992
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a The University of Alabama at Birmingham. $b Neurobiology. $3 1474772
773 0 $t Dissertations Abstracts International $g 85-06B.
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=30689974 $z click for full text (PQDT)